DFMO (eflornithine / TADPOL)
What it is
An oral polyamine-pathway inhibitor being studied to reduce beta-cell stress. A small safety trial found an early C-peptide signal; the 74-participant TADPOL study has no posted results.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2026-08-21. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Regrowth efficacy: The 41-person dose-ranging trial found a high-dose C-peptide signal; this small secondary analysis needs confirmation.[1]
- Important harms and treatment burden
- Safety: The early safety endpoint was met, but one participant withdrew after urticaria and symptoms of anaphylaxis.[1]
- Approval and country access
- An oral polyamine-pathway inhibitor being studied to reduce beta-cell stress. A small safety trial found an early C-peptide signal; the 74-participant TADPOL study has no posted results.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: The early trial followed participants for three months after dosing; long-term benefit is unknown.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 25 × 30 + 15 × 15 + 40 × 15 + 30 × 15 + 25 × 25 = 2650; divide by total weight 100. Unrounded weighted result: 26.5.
The 41-person dose-ranging trial found a high-dose C-peptide signal; this small secondary analysis needs confirmation.[1]
The early trial followed participants for three months after dosing; long-term benefit is unknown.[1]
The early safety endpoint was met, but one participant withdrew after urticaria and symptoms of anaphylaxis.[1]
TADPOL selected ages 4–40 within 100 days of first insulin, with autoantibodies and residual C-peptide.[2]
Phase 2 is active, not recruiting, with 74 actual participants; results are not posted.[2]
The full picture
Preservation, not demonstrated regrowth
DFMO inhibits ornithine decarboxylase, an enzyme involved in polyamine production. The proposed benefit is reduced beta-cell stress. Its placement in the regeneration category groups research on restoring or preserving function; it does not mean DFMO has grown new beta cells in people.1
The published early trial randomized 41 people (31 drug, 10 placebo). The highest-dose cohort contained only six people. Safety was the primary endpoint; C-peptide findings were secondary, and the study was not a confirmatory efficacy trial. Reported events included gastrointestinal symptoms, headaches and an allergic withdrawal. Three months of treatment and three months of follow-up cannot establish rare or long-term risks.1
TADPOL
The current Phase 2 registry lists 74 actual participants, active but not recruiting, with estimated completion in June 2027. Oral treatment lasts six months followed by follow-up. No Phase 2 results are posted; enrolment is not an efficacy denominator.2
The early registry retains an older planned allocation that differs from the published trial. This entry uses the publication for what actually happened and the TADPOL registry for current trial status.
Sources
- [1]Inhibition of polyamine biosynthesis preserves beta-cell function in type 1 diabetes · peer-reviewed · 2023-11-01
- [2]NCT05594563 — study record · registry · 2026-08-21 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.
- [3]NCT02384889 — study record · registry · 2021-09-05 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.